¿Las mujeres de alto riesgo (p. ej., portadoras de BRCA) se arrepienten de la mastectomía reductora de riesgo — o de haber elegido la vigilancia?
Si actúas
Someterse a una mastectomía reductora de riesgo (profiláctica)
19%
Si no actúas
Elegir vigilancia intensificada en lugar de cirugía
14%
Porcentaje de quienes luego se arrepienten de cada elección. Las barras y el registro completo aparecen abajo.
Salud
Última revisión 2026-07-14
Calidad de la evidencia 4.25/5
Puntuación de revisión en ocho dimensiones según la
rúbrica de calidad
. Cada dimensión puntuada de 1 a 5.
D1 Verificación de fuentes
5/5
D2 Autoridad e independencia de las fuentes
5/5
D3 Precisión de la tasa de arrepentimiento
3/5
D4 Comparabilidad de las fuentes
3/5
D5 Patrón de Gilovich
4/5
D6 Calidad de la prosa
5/5
D7 Completitud de las advertencias
5/5
D8 Calidad de la muestra
4/5
Media4.25/5
Datos sustitutos — no existe ninguna encuesta directa sobre el arrepentimiento para esta decisión. Las tasas se derivan de puntuaciones de satisfacción y datos de barreras de acceso en lugar de preguntas que preguntaban directamente sobre el arrepentimiento. Ver advertencias más abajo.
Arrepentimiento por acción
Someterse a una mastectomía reductora de riesgo (profiláctica)
19%
19% insatisfechas con el procedimiento una media de 14,5 años después (Frost); en una cohorte aparte, el 7% no volvería a elegir la operación y el 33% encontró que el resultado estético no era el esperado
Portadoras de BRCA / mujeres de alto riesgo tras mastectomía profiláctica bilateral
media de 14,5 años tras el procedimiento
Arrepentimiento por inacción
Elegir vigilancia intensificada en lugar de cirugía
14%
sin encuesta directa de arrepentimiento — indicador indirecto: la preocupación por el cáncer sube en lugar de bajar bajo vigilancia, y el 14% de quienes eligieron vigilancia desarrolló cáncer de mama (28/201 en una mediana de 5,9 años; 9,9% acumulado a 5 años)
Portadoras de BRCA / mujeres de alto riesgo que eligen vigilancia mamaria intensificada
incidencia bruta en una mediana de 5,9 años de seguimiento; preocupación medida a lo largo de 6–8 meses
% que se arrepienten de esta elección
Someterse a una mastectomía reductora de riesgo (profiláctica)Elegir vigilancia intensificada en lugar de cirugía
At long follow-up, roughly one in five women is dissatisfied with a risk-reducing mastectomy. The largest long-term study — 572 women a mean of 14.5 years after bilateral prophylactic mastectomy at the Mayo Clinic — found 19% dissatisfied with the procedure, alongside 74% who reported diminished emotional concern about developing breast cancer (Frost et al., 2000). That dissatisfaction is mostly about the body rather than the decision: about a third reported an unfavourable effect on satisfaction with body appearance, and a quarter on feelings of femininity. An independent Norwegian cohort of BRCA1/2 carriers pins the narrower figure down — only about 7% would not choose the same operation again, though a third said the cosmetic result was not as expected, and lower satisfaction clustered among women who found the decision process difficult or felt unsupported by their clinicians (Hyldebrandt et al., 2025). The regret that exists tends to attach to reconstruction complications and to decisions that felt externally initiated, not to the cancer-risk reduction the surgery reliably delivers.
The surveillance side has no direct regret survey at all, so its rate is a proxy assembled from two things. First, the harm that materialises: in a Canadian cohort, 14% of women who chose surveillance developed breast cancer (9.9% cumulative at five years), against 6% among those awaiting surgery (Macadam et al., 2021). Second, the burden that persists: on the one measure taken comparably on both arms — cancer worry — surgery lowers it and surveillance does not. A prospective cohort found anxiety fell over six to eight months in women who chose mastectomy but rose in women who chose surveillance, ending higher in the surveillance group (Dick et al., 2022). Developing a cancer is not the same as regretting the choice, and many surveillance-detected cancers are caught early, so the 14% inaction figure is a materialised-harm-plus-worry stand-in, not a measured regret rate.
The two numbers land close together, but the closeness is fragile: it depends on which proxy anchors each side. They are not measuring the same thing — the action rate is long-term dissatisfaction with an irreversible operation, while the inaction rate is cancer incidence plus unresolved worry among women who kept their breasts. Swap the broad 19% dissatisfaction for the narrower 7% who would not choose the surgery again, and the balance tips toward surveillance; anchor the inaction side on the 9.9% five-year cumulative incidence instead of the 14% crude rate, and it tips the other way. On the worry axis alone the surveillance side carries more — the Gilovich-typical pattern in which the road not taken keeps generating unease — but risk-reducing mastectomy is permanent and exacts body-image and reconstruction costs that surveillance never imposes, which is what holds the action-side dissatisfaction up to meet it. None of the underlying data is a US survey of the surveillance arm, and no study asks surveillance-choosers directly whether they would decide differently, so the near-balance is a direction with wide error bars, not a settled equivalence.
Fuentes: acción
Registro de evidencia
Cada número a continuación es lo que reportó cada fuente, con la cita textual en la que nos basamos y cómo llegamos a nuestra cifra. Haz clic en cualquier enlace para verificarlo directamente.
[1]JAMA (Frost et al. 2000, Mayo Clinic) — Long-term satisfaction and psychological and social function following bilateral prophylactic mastectomy
Revisado por pares
Among 572 women (94% of survivors), mean 14.5 years after bilateral prophylactic mastectomy: 70% satisfied with the procedure, 11% neutral, 19% dissatisfied; 74% reported a diminished level of emotional concern about developing breast cancer; negative effects were reported on satisfaction with body appearance (36%) and on feelings of femininity (25%)
Extracto
“"Most women (70%) were satisfied with the procedure; 11% were neutral; and 19% were dissatisfied. Among the psychological and social variables, the most striking finding was that 74% reported a diminished level of emotional concern about developing breast cancer. The majority of women reported no change/favorable effects in levels of emotional stability (68%/23%), level of stress (58%/28%), self-esteem (69%/13%), sexual relationships (73%/4%), and feelings of femininity (67%/8%). Forty-eight percent reported no change in their level of satisfaction with body appearance; 16% reported favorable effects. However, 9%, 14%, 18%, 23%, 25%, and 36% reported negative effects in these 6 variables, respectively."
”
Datos de la fuente de
2000-07-19
Accedido
2026-07-14
Cálculo
The action-side anchor. Frost et al. is the largest long-term follow-up of prophylactic mastectomy (n=572, mean 14.5 years, US Mayo Clinic cohort) and the standard reference for durable outcomes. It measures satisfaction, not "regret" directly: 19% were dissatisfied with the procedure at long follow-up, which we take as the action-side proxy for a lingering negative decision outcome. This overlaps with — but is broader than — outright decision regret (see the Hyldebrandt cohort, where only ~7% would not choose the operation again). The 19% dissatisfied largely reflects body-image, femininity, and cosmetic outcomes rather than a wish to have skipped the surgery altogether.
[2]Familial Cancer (Hyldebrandt et al. 2025) — Experiences with risk-reducing mastectomy in Norwegian BRCA1/2 carriers without prior breast cancer
Revisado por pares
Of 190 BRCA1/2 carriers who had undergone risk-reducing mastectomy: 78.9% (150/190) satisfied and would choose the same procedure again; 13 (6.8%) would not choose the same operation again; 63 women (33%) said the operative result was not as expected; satisfaction with healthcare-system support gave an OR of 5.5 for being satisfied with RRM (p<0.01), and finding the decision difficult lowered the odds (OR 0.2, p=0.02)
Extracto
“"78.9% (150/190) were satisfied with their decision and would choose the same procedure again. [...] 13 (6.8%) [would not have chosen the same operation]. [...] 63 women (33%) expressed that the result was not as expected. [...] Feeling satisfied with support from the health care system gave an OR of 5.5 for being satisfied with having undergone RRM (p < 0.01). Those who found the decision difficult had lower odds of being satisfied (OR 0.2, p = 0.02)."
”
Datos de la fuente de
2025-01-01
Accedido
2026-07-14
Cálculo
Independent corroboration from a Norwegian cancer-unaffected BRCA1/2 cohort (n=190 who had RRM, of 272 respondents). It supplies the cleaner decision-regret figure: 6.8% would not choose the operation again — a floor well below Frost's 19% dissatisfaction, because "dissatisfied with the result" and "would not do it again" are different constructs. The third of women whose result was "not as expected" tracks the same body-image/reconstruction dissatisfaction Frost measures. The finding that a difficult decision process and weak healthcare support predict lower satisfaction is the source for the prose claim that RRM regret concentrates around reconstruction outcomes and decisions that felt externally driven rather than chosen.
Fuentes: inacción
Registro de evidencia
Cada número a continuación es lo que reportó cada fuente, con la cita textual en la que nos basamos y cómo llegamos a nuestra cifra. Haz clic en cualquier enlace para verificarlo directamente.
[1]Hereditary Cancer in Clinical Practice (Dick et al. 2022) — Psychological factors and the uptake of preventative measures in BRCA1/2 pathogenic variant carriers: results of a prospective cohort study
Revisado por pares
Prospective cohort (n=98). Anxiety in the intensified-breast-surveillance (IBS) group rose over 6–8 months (mean ~6.2 → ~6.6), while anxiety in the risk-reducing-mastectomy group, elevated just after test-result disclosure (T1 ~8.2, up from ~7.6 at baseline), fell to ~5.7 over the same period; elevated post-disclosure anxiety predicted opting for RRM (OR 1.2, p<0.01)
Extracto
“"Baseline anxiety levels in women opting for RRM were high but decreased over time, while they increased in women opting for intensified breast surveillance (IBS). [...] Elevated levels of anxiety after genetic test result disclosure (T1) were associated with the decision to undergo RRM (p < 0.01; OR = 1.2, 95% CI = 1.05–1.42)." [Reported group means: RRM T1 8.2 → T2 5.7; IBS T1 6.2 → T2 6.6, so at follow-up the surveillance group's mean anxiety (6.6) exceeded the mastectomy group's (5.7).]
”
Datos de la fuente de
2022-12-01
Accedido
2026-07-14
Cálculo
The construct-matched half of the inaction proxy, and the reason the two sides can be compared at all. On the one axis measured comparably on both arms — psychological burden / cancer worry — surgery lowers it and surveillance does not: the surveillance group's anxiety rose and ended higher than the mastectomy group's. This is the residual worry that is the honest analogue of "regret" for the surveillance choice. It is not a regret rate and yields no percentage; it fixes the direction of the worry burden, not the magnitude.
[2]Current Oncology (Macadam et al. 2021) — Prophylactic Surgery in the BRCA+ Patient: Do Women Develop Breast Cancer While Waiting?
Revisado por pares
Of 333 BRCA carriers, 201 chose surveillance and 132 chose prophylactic mastectomy with immediate reconstruction. 28/201 surveillance patients (13.9%) developed invasive breast cancer vs 8/132 (6.1%) in the surgery group; 5-year cumulative incidence 9.9% (surveillance) vs 4.9% (surgery). 89% of surveillance-detected tumours were <20 mm
Extracto
“"During this period, 6% of patients developed breast cancer compared with a 14% incidence of breast cancer in patients choosing surveillance. [...] At five years, the cumulative incidence of breast cancer in the surveillance group was 9.9% compared with 4.9% in the PM/IBR group." [Results: "201 patients chose S, 132 chose PM/IBR"; "Twenty-eight of the 201 surveillance patients and eight of 132 patients in the PM/IBR group developed invasive breast cancer"; median surveillance follow-up 5.9 yr; 89% of tumours <20 mm.]
”
Datos de la fuente de
2021-02-01
Accedido
2026-07-14
Cálculo
The materialized-harm anchor for the inaction proxy. The inaction-side rate is set at 0.14 — the crude cited figure: 28 of 201 surveillance-choosers (13.9%) developed invasive breast cancer in this Canadian cohort over a median 5.9 years. No worry adjustment is applied; an earlier draft nudged this to 0.15 to "fold in" the rising cancer worry, but that increment has no source basis (Dick 2022 yields no regret percentage) and has been removed. The 5-year cumulative incidence of 9.9% is the alternative anchor; choosing it instead would move the rate to ~0.10 and the delta to ~0.09. Developing cancer is not itself "regret" — 89% of the surveillance-detected tumours were under 20 mm, i.e. screen-caught early, and no survey asks surveillance-choosers whether they regret the decision — so this is a materialized-harm-plus-worry proxy, not a regret survey. It is the closest available inaction anchor and is deliberately flagged as a proxy. Boundary call: with action 0.19 and inaction 0.14 the delta is exactly 0.05, sitting right on the rubric's balanced/action_dominates line (|delta| < 0.05 is balanced). The label is deliberately kept at "balanced" rather than tipped to "action_dominates" because the two rates are non-comparable proxies (long-term dissatisfaction vs materialized cancer incidence); a signed delta at the boundary between them carries no interpretable direction, so "neither side clearly dominates" is the honest reading.
Advertencias
Ambas tasas son indicadores indirectos procedentes de cohortes no comparables, y esta entrada se publica con una advertencia de proxy por esa razón. El 19% del lado de la acción es una cifra de satisfacción/insatisfacción medida una media de 14,5 años después de la mastectomía profiláctica bilateral (Frost 2000, EE. UU., n=572); la cifra más limpia de arrepentimiento de la decisión, de una cohorte BRCA independiente, es mucho más baja — alrededor del 7% no volvería a elegir la operación (Hyldebrandt 2025, Noruega, n=190), y un tercio informó que el resultado estético no era el esperado. El 14% del lado de la inacción no es en absoluto una tasa de arrepentimiento: está anclado en el 14% de quienes eligieron vigilancia y desarrollaron cáncer de mama (Macadam 2021, Canadá, n=201; 28/201 en una mediana de 5,9 años, 9,9% acumulado a 5 años), un daño materializado, con la trayectoria ascendente de la preocupación por el cáncer bajo vigilancia (Dick 2022, Europa, n=98) como corroboración de constructo equivalente. Ninguna encuesta publicada pregunta directamente a las mujeres que eligieron vigilancia si se arrepienten, así que la tasa de inacción arrastra una incertidumbre amplia. Los dos lados miden constructos distintos — insatisfacción a largo plazo con una cirugía irreversible frente a incidencia de cáncer más preocupación residual — de modo que el delta de 0.05 se sitúa en la frontera del equilibrio y no es una magnitud interpretable en ninguna dirección; debe leerse como "ningún lado domina claramente", no como una igualdad precisa ni como que la acción se lamenta más. Ese casi-equilibrio es además, en parte, un artefacto de la elección de anclas: tomar la cifra más limpia de arrepentimiento de la decisión para el lado de la acción (el 7% de Hyldebrandt que no volvería a elegirla, en lugar del 19% de insatisfacción de Frost) invertiría el signo hacia la inacción, mientras que tomar la incidencia acumulada a cinco años del 9,9% para el lado de la inacción ampliaría la brecha hasta cerca de 0.09. El equilibrio es, por tanto, una propiedad de qué proxies se eligieron, no un hallazgo. El único eje medido de forma comparable en ambos brazos, la carga psicológica, se inclina hacia el lado de la vigilancia: la preocupación baja tras la cirugía y sube bajo vigilancia, el patrón de inacción típico de Gilovich. Frente a eso, la mastectomía profiláctica es irreversible y conlleva costes de imagen corporal, feminidad y complicaciones de la reconstrucción que la vigilancia no tiene, que es lo que mantiene la insatisfacción del lado de la acción lo bastante alta como para compensarlo. Las poblaciones son estadounidense, noruega, canadiense y europea; ninguno de los datos de arrepentimiento/satisfacción es una encuesta estadounidense del brazo de vigilancia. El arrepentimiento tras la mastectomía reductora de riesgo se concentra en las complicaciones de la reconstrucción, las expectativas estéticas no cumplidas y las decisiones que se sintieron iniciadas desde fuera en lugar de elegidas (Hyldebrandt 2025) — no en la reducción del riesgo de cáncer en sí, que la cirugía proporciona de forma fiable.
